Injection-site reaction

3 papers

Trial sponsors

Duke University
2 trialsPhase 41,024 people

Latest

6 in 12 months

Current Atherosclerosis ReportsYesterday

RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms

ReviewInterventions

Journal of Clinical Lipidology7 Oct

Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review

Systematic reviewInterventions

The Annals of Pharmacotherapy26 Sep

Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia

Systematic review of randomised trialsFamilial hypercholesterolemia

Lancet28 Aug

Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Randomised trial in 70 peopleInterventions

Naunyn-Schmiedeberg's Archives of Pharmacology18 Aug

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials

Meta-analysis of randomised trialsInterventions

Dermatologic Surgery29 May

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity

ReviewGLP-1 receptor agonists

Diseases27 May

A Closer Look at the Dermatological Profile of GLP-1 Agonists

ReviewInterventions